SiSaf Ltd, an RNA therapeutics company, is pleased to announce the publication in the peer-reviewed journal Molecular Therapy Nucleic Acids(1) of positive in vivo data demonstrating the safety and efficacy of its siRNA therapy for Autosomal Dominant Osteopetrosis 2 (ADO2). The data reported in the paper demonstrate .
Peer-Reviewed Publication of Positive Preclinical Data of SiSaf s SIS-ADO2 siRNA Program to Treat Rare Genetic Bone Disorder Osteopetrosis tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
SiSaf Appoints Nikos Tzagkarakis in the New Role of Chief A.I. Officer Guildford, England – 13 July 2023 – RNA delivery and therapeutics company SiSaf Ltd announces that it has appointed Nikos Tzagkarakis in the newly created role of Chief A.I. Officer. The new position reflects the.
GUILDFORD, England, July 13, 2023 (GLOBE NEWSWIRE) RNA delivery and therapeutics company SiSaf Ltd announces that it has appointed Nikos Tzagkarakis in the newly created role of Chief A.I. Officer. The new position
SiSaf has been granted Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (PRDD) by the US Food and Drug Administration (FDA) for its osteopetrosis treatment, SIS-101-ADO.